You are hereApril 16, 2018
What’s the Stem Cells Buzz this Week? - Prostate Progenitor Cell Activity, Healing by iPSC-Derived MSCs, MINDY1 and ESC Self‐Renewal, and Stem Cell Therapy for Corneal Scarring!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
Intestinal Healing By iPSC-Derived MSCs
The generation of mesenchymal stem cells (MSCs) from patient-specific induced pluripotent stem cells (iPSCs) may represent a convenient source of autologous cells for therapeutic purposes. To test this approach, researchers from the lab of Steven Dow (Colorado State University, USA) compared iPSC-MSCs with adipose-derived MSCs in a mouse model of intestinal protection. Encouragingly, Soontararak et al. discovered that both MSCs types improved overall intestinal health and healing with equivalent potency and therefore, iPSC-MSCs may represent a new therapy for irritable bowel syndrome and other related diseases/disorders. See STEM CELLS Translational Medicine now for all the fine print.
MAO Loss Impairs Prostate Progenitor Cell Activity
To study the influence of monoamine oxidases (MAOs) during mammalian development, researchers from the laboratory of Boyang Jason Wu (Washington State University, USA) investigated a mouse model lacking both MAO isoforms (A and B). Yin et al. established that MAO loss led to prostate atrophy with reduced prostate basal and stem/progenitor cell activity in adult mice, thereby providing insight into the maintenance of prostate structure and function. Furthermore, the team sees possible implications in their work for the development of new treatments for prostatic hyperplasia and prostate cancer. Read all the details at STEM CELLS now.
MINDY1 and Embryonic Stem Cell Self‐Renewal
Previous publications from the lab of Leah A. Vardy (A*STAR, Singapore) determined the critical nature of the polyamine regulator AMD1 for embryonic stem cell self‐renewal. The team now returns with a new study that highlights the relative importance of MINDY1, a new stem cell regulator that acts downstream of the polyamines. James et al. discovered the requirement for high polyamine levels for ESC self‐renewal and that polyamines function, in part, through the promotion of high MINDY1 levels. For more on MINDY1, head over to STEM CELLS now!
Enhanced Stem Cell Therapy for Corneal Scarring
A new study from the lab of James L. Funderburgh (University of Pittsburgh, Pennsylvania, USA) recently sought to explore the potential for compressed collagen gel (CCG) as a vehicle to deliver corneal stromal stem cells (CSSCs) to suppress corneal stromal scarring in a mouse wound‐healing model and promote regeneration of native transparent tissue. Their new STEM CELLS Translational Medicine study now demonstrates that these gels facilitate handling, storage, and transfer of cells to the eye, and gel‐embedded cells exhibit greater potency for corneal regeneration than stem cells alone.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!